HR Execs on the Move

Burbank HealthCare Foundation

www.burbankhcf.org

 
Burbank HealthCare Foundation is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

BLOSSOM SOUTH

BLOSSOM SOUTH is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Orleans BioInnovation Center

New Orleans BioInnovation Center is a New Orleans, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

First Choice Health

First Choice Health is a Seattle-based, physician and hospital owned company that has served Washington and the Northwest since 1985. We now serve well over one million people with our array of products and services. First Choice Health`s Preferred Provider Organization (PPO) is recognized as the leading independent PPO Network in Washington and Oregon, with a growing regional presence in Alaska, Idaho, Montana, Wyoming, and beyond. Combined our network offers over 120,000 directly contracted and credentialed providers and 369 hospitals used by a wide variety of insurance companies, third party administrators, and plan sponsors. In addition to our PPO Network, First Choice Health offers Medical Management Services, an Employee Assistance Program (EAP), a Physician Assistance Program (PAP), and Health Plan Administration (HPA).

Magellan Medicaid Administration

Magellan Medicaid Administration is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.